このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

IB2-IVA 子宮頸がんまたは膣がん患者の治療における化学療法および放射線療法によるトリアピン

2026年11月11日 更新者:National Cancer Institute (NCI)

局所進行子宮頸がん(LACC)および膣がんに対する同時化学放射線療法と組み合わせた経口トリアピンの第I相用量漸増バイオアベイラビリティ研究

This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.

II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.

SECONDARY OBJECTIVES:

I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.

II. To determine clinical overall response rate, progression-free survival, and overall survival.

III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.

EXPLORATORY OBJECTIVE:

I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.

OUTLINE: This is a dose-escalation study of triapine.

Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.

研究の種類

介入

入学 (実際)

21

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama at Birmingham Cancer Center
    • California
      • Los Angeles、California、アメリカ、90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles、California、アメリカ、90033
        • Los Angeles General Medical Center
      • Pasadena、California、アメリカ、91105
        • Keck Medical Center of USC Pasadena
    • Kansas
      • Fairway、Kansas、アメリカ、66205
        • University of Kansas Clinical Research Center
      • Kansas City、Kansas、アメリカ、66160
        • University of Kansas Cancer Center
      • Overland Park、Kansas、アメリカ、66211
        • University of Kansas Hospital-Indian Creek Campus
      • Westwood、Kansas、アメリカ、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky/Markey Cancer Center
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • University of Michigan Rogel Cancer Center
      • Detroit、Michigan、アメリカ、48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills、Michigan、アメリカ、48334
        • Weisberg Cancer Treatment Center
    • New Jersey
      • New Brunswick、New Jersey、アメリカ、08903
        • Rutgers Cancer Institute of New Jersey
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Charlottesville、Virginia、アメリカ、22908
        • University of Virginia Cancer Center
      • Richmond、Virginia、アメリカ、23298
        • VCU Massey Comprehensive Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan

  • Age >= 18 years old

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

  • Life expectancy greater than 6 months

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

  • Platelets >= 100 x 10^9/L

  • Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)

  • Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin

    • If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
  • Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

  • Able to take oral medication

  • Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study

  • For HIV and hepatitis B/C (HEPB/C):

    • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Able to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
  • Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
  • Patients receiving any other investigational agents
  • Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
  • Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
  • Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
  • Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (triapine, chemoradiation)

Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.

Given IV

他の名前:
  • CDDP
  • シスジアミンジクロリド白金
  • シスマプラット
  • シスプラチナム
  • ネオプラチン
  • プラチノール
  • アビプラチン
  • ブラストレム
  • ブリプラチン
  • シス-ジアミン-ジクロロ白金
  • シス-ジアミンジクロロ 白金(II)
  • シスジアミンジクロロ白金
  • Cis-ジクロロアミン プラチナ (II)
  • シス白金ジアミンジクロリド
  • シスプラチナ
  • シスプラチナⅡ
  • シスプラチナⅡジアミンジクロリド
  • シスプラチル
  • シトプラチノ
  • シトシン
  • シスプラティナ
  • DDP
  • レーダープラチン
  • メタプラチン
  • ペイロンの塩化物
  • ペロンの塩
  • プラシス
  • プラススティル
  • プラタミン
  • プラチブラスチン
  • プラチブラスチン-S
  • プラティネックス
  • プラチノール-AQ
  • プラチノール-AQ VHA プラス
  • プラチノキサン
  • 白金
  • 白金ジアミノ二塩化物
  • プラティラン
  • プラティスチン
  • プラトシン

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Correlative studies

Undergo collection of blood samples

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Undergo IMRT

他の名前:
  • IMRT
  • 強度変調 RT
  • 強度変調放射線治療
  • 放射線、強度変調放射線治療
  • 強度変調放射線療法(手順)

Undergo FDG-PET/CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo FDG-PET/CT

他の名前:
  • 医用画像、陽電子放出断層撮影
  • ペット
  • PETスキャン
  • 陽電子放出断層撮影スキャン
  • 陽電子放出断層撮影
  • PT
  • 陽電子放出断層撮影(手順)

Undergo LDR brachytherapy

他の名前:
  • 小線源治療、NOS
  • 内部放射線
  • 内部放射線小線源治療
  • 内部放射線治療
  • 放射線小線源治療
  • 放射線、内部

Undergo pelvic EBRT

他の名前:
  • EBRT
  • 根治的放射線療法
  • 外部ビーム放射
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 放射線、外部ビーム
  • 遠隔放射線療法
  • 遠隔治療
  • 遠隔治療放射線
  • 外照射療法(従来)

Undergo FDG-PET/CT

他の名前:
  • 18FDG
  • FDG
  • フルデオキシグルコース F 18
  • フルデオキシグルコース (18F)
  • フルデオキシグルコース F18
  • フッ素-18 2-フルオロ-2-デオキシ-D-グルコース
  • フルオロデオキシグルコース F18

Undergo HDR brachytherapy

他の名前:
  • 小線源治療、高用量
  • HDR
  • 高線量近接照射療法(手順)

Given IV and PO

他の名前:
  • 3-アミノピリジン-2-カルボキシアルデヒド チオセミカルバゾン
  • 3-AP
  • 3-Apct
  • OCX-0191
  • OCX-191
  • OCX191
  • PAN-811

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
除去半減期 (t 1/2)
時間枠:投与後24時間以内
投与後24時間以内
Maximum Tolerated Dose (MTD)
時間枠:Up to 5 weeks

The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD

Up to 5 weeks
Number of Patients Who Experienced a DLT
時間枠:Up to 5 weeks

Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days.

Inability to deliver

Up to 5 weeks
Bioavailability of Triapine
時間枠:Up to 2 weeks

The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry.

Up to 2 weeks
Cmax
時間枠:Up to 24 hours after dosing

Maximum concentration

Up to 24 hours after dosing
Tmax
時間枠:Up to 24 hours after dosing

Time to maximum concentration,

Up to 24 hours after dosing
AUC
時間枠:Up to 24 hours after dosing

Area Under the Concentration-Time Curve (AUC 0-last)

Up to 24 hours after dosing

二次結果の測定

結果測定
メジャーの説明
時間枠
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
時間枠:At 3 months post-treatment

The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool).

At 3 months post-treatment
Clinical Overall Response Rate
時間枠:3 months post-treatment

Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

3 months post-treatment
Progression Free Survival (PFS)
時間枠:Up to 4 years and 2 months from start of treatment

Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Up to 4 years and 2 months from start of treatment
Overall Survival (OS)
時間枠:Up to 4 years and 2 months from start of treatment

Median number of months that patients remain alive after end of treatment.

Up to 4 years and 2 months from start of treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Sarah E Taylor、University of Pittsburgh Cancer Institute LAO

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年9月18日

一次修了 (実際)

2023年6月4日

研究の完了 (推定)

2027年4月29日

試験登録日

最初に提出

2015年11月3日

QC基準を満たした最初の提出物

2015年11月3日

最初の投稿 (推定)

2015年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する